// App-Quantinova.ai

7508 : High, durable minimal residual disease negativity (MRD) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

Researchers

Presenter

  • Peter Hillmen

Principal Investigators

  • John Francis Seymour

  • Anton W Langerak

  • Barbara Eichhorst

  • Carolyn Owen

  • Sarit E. Assouline

  • Ann Janssens

  • Paula Marlton

  • Xavier C. Badoux

  • Rogier Mous

  • Brenda Chyla

  • Rod Humerickhouse

  • Michelle Boyer

  • Kathryn Humphrey

  • Yanwen Jiang

  • Elizabeth Punnoose

  • Jue Wang

  • Qun Jenny Wu

  • Mehrdad Mobasher

Medical Centers

  • St. James's University Hospital, Leeds, United Kingdom

  • Academic Medical Center, Amsterdam, Netherlands

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Department of Immunology, Erasmus Medical Center, Rotterdam, Netherlands

  • University of Cologne, Cologne, DE, Germany

  • University of Calgary, Calgary, AB, Canada

  • Jewish General Hospital, Montreal, QC, Canada

  • Universitaire Ziekenhuizen Leuven, Leuven, Belgium

  • Princess Alexandra Hospital and University of Queensland, Brisbane, Australia

  • St George Hospital, Department of Haematology, NSW Health Pathology, Kogarah, Australia

  • UMC Utrecht Cancer Center, Utrecht, Netherlands

  • AbbVie, Inc., North Chicago, IL

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • Genentech, Inc., South San Francisico, CA

Locations

  • Canada

  • Netherlands

  • Germany

  • United Kingdom

  • Australia

  • United States

  • Belgium

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02005471

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved